查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1949582

犬用疫苗市場－全球產業規模、佔有率、趨勢、機會與預測：疫苗類型、疾病類型、免疫持續時間、給藥途徑、地區和競爭格局（2021-2031年）

Dog Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Vaccine Type, By Disease Type, By Duration of Immunity, By Route of Administration, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球犬用疫苗市場預計將從 2025 年的 19.7 億美元成長到 2031 年的 28.8 億美元，複合年成長率為 6.53%。

這些生物製藥對於刺激犬隻免疫系統抵抗某些病原體（例如狂犬病和犬瘟熱）至關重要。推動市場成長的主要因素是人們對通用感染疾病的認知不斷提高，這些疾病需要嚴格的預防保健；此外，寵物人性化趨勢也增加了獸醫服務的支出。根據美國獸醫協會（AVMA）預測，到2024年，美國犬隻數量將達到約8,970萬隻，凸顯了龐大的基本客群對市場需求的巨大推動作用。

市場概覽
預測期 2027-2031
市場規模：2025年 19.7億美元
市場規模：2031年 28.8億美元
複合年成長率：2026-2031年 6.53%
成長最快的細分市場 口服
最大的市場 北美洲

然而，市場擴張面臨許多重大障礙：產品研發和核准的法規結構十分複雜。製造商必須遵守嚴格的安全通訊協定並大規模的臨床試驗，這需要大量的投資和時間。這種嚴格的監管環境往往會延緩創新疫苗的上市，並限制不同地區（合規標準各異）的市場進入，最終減緩整個產業的成長速度。

市場促進因素

寵物人性化的趨勢和寵物飼養率的不斷上升，從根本上改變了人們對犬類疫苗的需求。隨著飼主越來越將犬隻視為家庭成員而非工作動物，他們更願意投資於全面的醫療保健，並提倡嚴格遵守獸醫通訊協定，以最大限度地延長寵物的壽命。例如，英國寵物食品協會發布的《2024年寵物數量報告》預測，到2024年3月，英國的犬隻數量將達到1350萬隻，這凸顯了犬隻數量的高密度，需要持續接種疫苗以維持群體免疫。

同時，通用和感染疾病的蔓延是市場成長的主要驅動力，促使政府主導嚴格的管制措施。當局正在強制推行疫苗接種，以防止狂犬病等高致死性病原體的爆發，這些病原體也對人類構成威脅。越南政府入口網站於2024年3月發布的一項指令凸顯了這種緊迫性，該指令要求在今年稍早發生22例狂犬病相關死亡事件後即時進行疫苗接種。為了支撐這一產業規模，碩騰公司在2024年2月的財務報告中公佈了85億美元的總收入，這反映出其在動物用藥品研發方面獲得了雄厚的資金支持。

市場挑戰

全球犬用疫苗市場面臨的主要障礙之一是獸用生技藥品監管框架的複雜性。這種分散的國際格局要求嚴格的安全通訊協定、有效性測試和強制性臨床試驗，迫使製造商在特定地區的合規性方面投入巨資，並導致研發資源分散。因此，這些嚴格的標準提高了進入門檻，阻礙了小型生技公司的進入，並將市場力量集中在少數幾個主要企業手中。

此外，漫長的核准週期顯著延緩了新型免疫解決方案的商業化進程，並阻礙了業界應對新興感染疾病的能力。根據2024年動物健康研究所的數據，新型獸用生技藥品的審查和核准流程需要五到七年。如此漫長的流程限制了製造商產品推出的速度，而維持研發階段的高昂成本則降低了投資報酬率，並限制了新疫苗上市的頻率。

市場趨勢

犬類腫瘤治療中免疫療法的興起標誌著治療方式從單純的預防性醫療轉向治療性生物干預，利用自體腫瘤抗原或重組蛋白標靶治療骨肉骨癌等惡性腫瘤。這種方法為傳統化療提供了一種精準的替代方案，可降低全身毒性，旨在延長進行性腫瘤患者的存活期。根據 Vet Candy 於 2025 年 8 月報道，一項新型 EGFR/HER2 標靶疫苗的臨床試驗顯示，12 個月存活率顯著提高，從約 35% 提高到 60%。

同時，重組和DNA疫苗技術的應用正在重塑疫苗生產流程，以基因工程載體取代傳統的去活化病原體。這項技術能夠生產高純度、非感染性抗原，從而提高安全性，並實現對感染動物和接種動物的區分（DIVA），這對於疾病根除至關重要。主要企業正在擴大這些平台的規模，默克動物保健公司在2025年2月宣布的59億美元年收入便是明證，這凸顯了商業性對先進動物保健技術的強勁需求。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球犬用疫苗市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依疫苗類型（減毒活病毒疫苗、不活化疫苗、其他）
    • 依疾病類型分類（犬瘟熱、犬傳染性呼吸道疾病症候群 (CIRDC)、犬小病毒感染疾病/細小病毒病、犬鉤端螺旋體病、犬萊姆病、犬傳染性肝炎、犬狂犬病等）
    • 免疫持續時間（1年、3年或其他）
    • 給藥途徑（注射、鼻腔、口服）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美犬用疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲犬用疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區犬用疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲犬用疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美犬用疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球犬用疫苗市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Zoetis Inc.
  • Bioveta as
  • Hester Biosciences Limited
  • Boehringer Ingelheim International GmbH
  • Brilliant Bio Pharma Private Limited
  • Heska Corporation
  • Merck & Co., Inc.
  • Virbac SA
  • Zendal Group
  • Elanco Animal Health Incorporated

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 27122

The Global Dog Vaccines Market is projected to expand from USD 1.97 Billion in 2025 to USD 2.88 Billion by 2031, registering a CAGR of 6.53%. These biological preparations are essential for stimulating canine immune systems against specific pathogens like rabies and distemper. Growth is primarily fuelled by heightened awareness of zoonotic diseases, necessitating rigorous preventive care, alongside the trend of pet humanization which increases spending on veterinary services. According to the American Veterinary Medical Association, the United States dog population stood at approximately 89.7 million in 2024, highlighting the vast customer base driving demand.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.97 Billion
Market Size 2031USD 2.88 Billion
CAGR 2026-20316.53%
Fastest Growing SegmentOral
Largest MarketNorth America

However, market expansion faces a significant hurdle in the form of complex regulatory frameworks governing product development and approval. Manufacturers must adhere to stringent safety protocols and extensive clinical trials, requiring substantial investment and time. This rigid landscape often delays the release of innovative vaccines and restricts market access across regions with varying compliance standards, effectively slowing the industry's overall growth trajectory.

Market Driver

The trend of pet humanization and rising ownership rates are fundamentally altering the demand for canine immunizations, as owners increasingly view dogs as family members rather than working animals. This shift promotes a willingness to invest in comprehensive preventive healthcare, ensuring rigorous adherence to veterinary protocols to maximize pet longevity. For instance, UK Pet Food's 'Pet Population 2024' report noted that the United Kingdom's dog population reached 13.5 million in March 2024, emphasizing the dense population requiring consistent vaccination for herd immunity.

Simultaneously, the prevalence of zoonotic and infectious diseases serves as a major catalyst for market growth, prompting strict government-led control measures. Authorities are enforcing vaccination mandates to prevent outbreaks of high-mortality pathogens like rabies, which poses risks to humans. The urgency is evident in the Vietnam Government Portal's March 2024 directive following 22 rabies-related deaths early in the year, calling for immediate vaccination coverage. Supporting this industrial scale, Zoetis reported $8.5 billion in total revenue in their February 2024 financial results, reflecting the massive capital backing animal health product development.

Market Challenge

A major barrier to the global dog vaccines market is the intricate regulatory framework governing veterinary biologics, which demands rigorous safety protocols, efficacy testing, and mandatory clinical trials. This fragmented international landscape compels manufacturers to invest heavily in region-specific compliance, diverting resources from research and development. Consequently, these stringent standards create high entry barriers that discourage smaller biotechnology firms and tend to consolidate market power among a few dominant entities.

Additionally, prolonged approval cycles significantly delay the commercialization of new immunization solutions, hindering the industry's response to emerging infectious diseases. Data from the Animal Health Institute in 2024 indicates that the review and approval process for new veterinary biologics takes between five and seven years. This extended timeline limits the speed at which manufacturers can launch products, while the high financial burden of sustaining such development phases reduces the return on investment and limits the frequency of necessary new vaccine introductions.

Market Trends

The rise of Therapeutic Immunotherapies for Canine Oncology marks a shift from purely prophylactic care to curative biological interventions, utilizing autologous tumor antigens or recombinant proteins to target malignancies like osteosarcoma. This approach offers a precision alternative to traditional chemotherapy with reduced systemic toxicity, aiming to extend the lives of patients with aggressive tumors. As reported by Vet Candy in August 2025, clinical trials for a novel EGFR/HER2-targeting vaccine showed a significant improvement in 12-month survival rates, jumping from approximately 35% to 60%.

Concurrently, the adoption of Recombinant and DNA Vaccine Technologies is reshaping manufacturing by replacing conventional inactivated pathogens with genetically engineered vectors. This technology produces highly pure, non-infectious antigens that improve safety and allow for the differentiation of infected from vaccinated animals (DIVA), which is vital for disease eradication. Major players are scaling these platforms, as evidenced by Merck Animal Health's reported full-year sales of $5.9 billion in February 2025, underscoring the strong commercial demand for advanced animal health innovations.

Key Market Players

  • Zoetis Inc.
  • Bioveta a.s
  • Hester Biosciences Limited
  • Boehringer Ingelheim International GmbH
  • Brilliant Bio Pharma Private Limited
  • Heska Corporation
  • Merck & Co., Inc.
  • Virbac S.A.
  • Zendal Group
  • Elanco Animal Health Incorporated

Report Scope

In this report, the Global Dog Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dog Vaccines Market, By Vaccine Type

  • Modified/ Attenuated Live
  • Inactivated (Killed)
  • Others

Dog Vaccines Market, By Disease Type

  • Canine Distemper
  • Canine Infectious Respiratory Disease Complex (CIRDC)
  • Canine Parvovirosis/ Parvovirus Disease
  • Canine Leptospirosis
  • Canine Lyme Disease
  • Infectious Canine Hepatitis
  • Canine Rabies
  • Others

Dog Vaccines Market, By Duration of Immunity

  • 1 Year
  • 3 Year
  • Others

Dog Vaccines Market, By Route of Administration

  • Injectables
  • Intranasal
  • Oral

Dog Vaccines Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dog Vaccines Market.

Available Customizations:

Global Dog Vaccines Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Dog Vaccines Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Vaccine Type (Modified/ Attenuated Live, Inactivated (Killed), Others)
    • 5.2.2. By Disease Type (Canine Distemper, Canine Infectious Respiratory Disease Complex (CIRDC), Canine Parvovirosis/ Parvovirus Disease, Canine Leptospirosis, Canine Lyme Disease, Infectious Canine Hepatitis, Canine Rabies, Others)
    • 5.2.3. By Duration of Immunity (1 Year, 3 Year, Others)
    • 5.2.4. By Route of Administration (Injectables, Intranasal, Oral)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Dog Vaccines Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Vaccine Type
    • 6.2.2. By Disease Type
    • 6.2.3. By Duration of Immunity
    • 6.2.4. By Route of Administration
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Dog Vaccines Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Vaccine Type
        • 6.3.1.2.2. By Disease Type
        • 6.3.1.2.3. By Duration of Immunity
        • 6.3.1.2.4. By Route of Administration
    • 6.3.2. Canada Dog Vaccines Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Vaccine Type
        • 6.3.2.2.2. By Disease Type
        • 6.3.2.2.3. By Duration of Immunity
        • 6.3.2.2.4. By Route of Administration
    • 6.3.3. Mexico Dog Vaccines Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Vaccine Type
        • 6.3.3.2.2. By Disease Type
        • 6.3.3.2.3. By Duration of Immunity
        • 6.3.3.2.4. By Route of Administration

7. Europe Dog Vaccines Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Vaccine Type
    • 7.2.2. By Disease Type
    • 7.2.3. By Duration of Immunity
    • 7.2.4. By Route of Administration
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Dog Vaccines Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Vaccine Type
        • 7.3.1.2.2. By Disease Type
        • 7.3.1.2.3. By Duration of Immunity
        • 7.3.1.2.4. By Route of Administration
    • 7.3.2. France Dog Vaccines Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Vaccine Type
        • 7.3.2.2.2. By Disease Type
        • 7.3.2.2.3. By Duration of Immunity
        • 7.3.2.2.4. By Route of Administration
    • 7.3.3. United Kingdom Dog Vaccines Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Vaccine Type
        • 7.3.3.2.2. By Disease Type
        • 7.3.3.2.3. By Duration of Immunity
        • 7.3.3.2.4. By Route of Administration
    • 7.3.4. Italy Dog Vaccines Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Vaccine Type
        • 7.3.4.2.2. By Disease Type
        • 7.3.4.2.3. By Duration of Immunity
        • 7.3.4.2.4. By Route of Administration
    • 7.3.5. Spain Dog Vaccines Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Vaccine Type
        • 7.3.5.2.2. By Disease Type
        • 7.3.5.2.3. By Duration of Immunity
        • 7.3.5.2.4. By Route of Administration

8. Asia Pacific Dog Vaccines Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Vaccine Type
    • 8.2.2. By Disease Type
    • 8.2.3. By Duration of Immunity
    • 8.2.4. By Route of Administration
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Dog Vaccines Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Vaccine Type
        • 8.3.1.2.2. By Disease Type
        • 8.3.1.2.3. By Duration of Immunity
        • 8.3.1.2.4. By Route of Administration
    • 8.3.2. India Dog Vaccines Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Vaccine Type
        • 8.3.2.2.2. By Disease Type
        • 8.3.2.2.3. By Duration of Immunity
        • 8.3.2.2.4. By Route of Administration
    • 8.3.3. Japan Dog Vaccines Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Vaccine Type
        • 8.3.3.2.2. By Disease Type
        • 8.3.3.2.3. By Duration of Immunity
        • 8.3.3.2.4. By Route of Administration
    • 8.3.4. South Korea Dog Vaccines Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Vaccine Type
        • 8.3.4.2.2. By Disease Type
        • 8.3.4.2.3. By Duration of Immunity
        • 8.3.4.2.4. By Route of Administration
    • 8.3.5. Australia Dog Vaccines Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Vaccine Type
        • 8.3.5.2.2. By Disease Type
        • 8.3.5.2.3. By Duration of Immunity
        • 8.3.5.2.4. By Route of Administration

9. Middle East & Africa Dog Vaccines Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Vaccine Type
    • 9.2.2. By Disease Type
    • 9.2.3. By Duration of Immunity
    • 9.2.4. By Route of Administration
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Dog Vaccines Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Vaccine Type
        • 9.3.1.2.2. By Disease Type
        • 9.3.1.2.3. By Duration of Immunity
        • 9.3.1.2.4. By Route of Administration
    • 9.3.2. UAE Dog Vaccines Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Vaccine Type
        • 9.3.2.2.2. By Disease Type
        • 9.3.2.2.3. By Duration of Immunity
        • 9.3.2.2.4. By Route of Administration
    • 9.3.3. South Africa Dog Vaccines Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Vaccine Type
        • 9.3.3.2.2. By Disease Type
        • 9.3.3.2.3. By Duration of Immunity
        • 9.3.3.2.4. By Route of Administration

10. South America Dog Vaccines Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Vaccine Type
    • 10.2.2. By Disease Type
    • 10.2.3. By Duration of Immunity
    • 10.2.4. By Route of Administration
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Dog Vaccines Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Vaccine Type
        • 10.3.1.2.2. By Disease Type
        • 10.3.1.2.3. By Duration of Immunity
        • 10.3.1.2.4. By Route of Administration
    • 10.3.2. Colombia Dog Vaccines Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Vaccine Type
        • 10.3.2.2.2. By Disease Type
        • 10.3.2.2.3. By Duration of Immunity
        • 10.3.2.2.4. By Route of Administration
    • 10.3.3. Argentina Dog Vaccines Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Vaccine Type
        • 10.3.3.2.2. By Disease Type
        • 10.3.3.2.3. By Duration of Immunity
        • 10.3.3.2.4. By Route of Administration

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Dog Vaccines Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Zoetis Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bioveta a.s
  • 15.3. Hester Biosciences Limited
  • 15.4. Boehringer Ingelheim International GmbH
  • 15.5. Brilliant Bio Pharma Private Limited
  • 15.6. Heska Corporation
  • 15.7. Merck & Co., Inc.
  • 15.8. Virbac S.A.
  • 15.9. Zendal Group
  • 15.10. Elanco Animal Health Incorporated

16. Strategic Recommendations

17. About Us & Disclaimer